New antibody drug takes on tough cancers
NCT ID NCT04931654
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an experimental drug called AZD7789 in people with advanced lung, stomach, or gastroesophageal cancer that cannot be removed by surgery. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The trial aims to check if the drug is safe and whether it can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AZD7789 (a bispecific antibody that targets PD-1 and TIM-3 proteins on immune cells)
What this could lead to
If it works, this could offer a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong
This is an early-phase trial with a small number of participants, so the drug may not prove effective or may cause unexpected side effects. Success is far from guaranteed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Atlanta, Georgia, 30322, United States
-
Research Site
Fort Wayne, Indiana, 46804, United States
-
Research Site
New York, New York, 10029, United States
-
Research Site
Nashville, Tennessee, 37203, United States
-
Research Site
Toronto, Ontario, M5G 2M9, Canada
-
Research Site
Beijing, 100142, China
-
Research Site
Guangzhou, 510060, China
-
Research Site
Bordeaux, 33076, France
-
Research Site
Rennes, 35000, France
-
Research Site
Villejuif, 94805, France
-
Research Site
Tbilisi, 0112, Georgia
-
Research Site
Chūōku, 104-0045, Japan
-
Research Site
Kashiwa, 277-8577, Japan
-
Research Site
Chisinau, MD-2025, Moldova
-
Research Site
Amsterdam, 1066 CX, Netherlands
-
Research Site
Barcelona, 08035, Spain
-
Research Site
Madrid, 28027, Spain
-
Research Site
Ankara, 06010, Turkey (Türkiye)
-
Research Site
Ankara, 06200, Turkey (Türkiye)
-
Research Site
Ankara, 06800, Turkey (Türkiye)
-
Research Site
Cordaleo, 35575, Turkey (Türkiye)